One pill to stop breast pain after pregnancy loss? new trial tests cabergoline
NCT ID NCT07492160
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether a single dose of cabergoline can prevent breast engorgement, milk leakage, and tenderness after abortion or pregnancy loss at 12-18 weeks. About 348 participants will receive either cabergoline or a placebo right after the procedure and report symptoms over two weeks. The goal is to see if the drug reduces bothersome breast symptoms compared to placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cabergoline
- What this could lead to
- If it works, this could offer a simple, single-dose option to prevent painful breast symptoms after pregnancy loss or abortion.
- What could go wrong
- This is a small, early-phase trial. The drug may not work better than placebo, and side effects like nausea or dizziness are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ABORTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Maimonides Medical Center
RECRUITINGBrooklyn, New York, 11219, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a class tame pregnancy stress at the genetic level?
- A nationwide test: do home visits build healthier families?
- Can a simple calcium tablet help prevent postpartum bleeding?
- Can AI read ultrasound sweeps to tell Baby's position?
- Could a smart ring unlock secrets of pregnancy health?
- Could Video-Led pelvic exercises redefine prenatal care?